Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,206.40
(
0.01%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.30
(
-0.89%
)
Bitcoin
77,816.10
(
-0.59%
)
News Focus
News Focus

Replies to post #889 on Fate Therapeutics Inc (FATE)

Replies to #889 on Fate Therapeutics Inc (FATE)
icon url

NY1972

12/14/25 11:10 PM

#890 RE: jondoeuk #889

Dr. V said patients are lined up for 836, not surprising since MSS stage 4 cancers have 0 effective treatment. LD taxol is TME modulator, combo with cetuximab showed high ORR in MSS CRC. Adding 836 to that would raise the ORR even higher,
icon url

NY1972

12/22/25 3:24 PM

#891 RE: jondoeuk #889

Dr. V added 2 new sites to treat stage 4 CRC pts. Nothing to see for the collective wisdom.